Last updated: 2026-09-06 08:15:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Omeros Corporation (OMER) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $18.93, with a market capitalization of $1.37B and a P/E ratio of 11.08. Over the past 52 weeks, its price has ranged from $3.94 to $19.65. This page covers its latest market performance, valuation, price trends and company information.
$1.37B | |
$19.00 | |
$30.23 | |
$0.92 | |
$19.11 | |
743.00K | |
-- | |
11.08 | |
$19.65 | |
$3.94 | |
-- | |
-- |
Omeros Corporation (OMER) last closed at $19.11 as of 2026-09-04 23:31:00, unchanged from the previous close of $19.11.
During the latest regular trading session, OMER traded between $0.92 and $30.23, with a volume of 743.00K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Omeros Corporation (OMER) moved from $18.54 to $18.93, representing a gain of 2.10% ($0.39).
The stock traded between $18.93 and $19.39 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 1.38 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 95.4%
OMER is currently trading at $18.93, placing it 95.4% of the way from its 52-week low of $3.94 to its 52-week high of $19.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 175 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Omeros Corporation (OMER) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.